Serial 98514227
Live / Registered — Registered (as of 21 Apr 2026)
What this means for you
Registered since 21 Apr 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 21 Apr 2032: the §8 declaration of use).
Record
- Serial number
- 98514227
- Registration number
- 8224385
- Mark type
- Design / logo
- Filed
- 23 Apr 2024
- Published for opposition
- 10 Dec 2024
- Registered
- 21 Apr 2026
- Next maintenance filing
- §8 declaration of use, due by 21 Apr 2032 (grace period to 21 Oct 2032)
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceuticals for the treatment of oncologic diseases
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Board proceedings on this mark
- Extension of Time to Oppose No. 98514227 — Sun Pharma Advanced Research Company Limited v. Johnson & Johnson, filed 09 Jan 2025 (Terminated)
Prosecution history
- 21 Apr 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Apr 2026 — REGISTERED-PRINCIPAL REGISTER
- 31 Mar 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 31 Mar 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 31 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 30 Sept 2025 — USE AMENDMENT FILED
- 30 Mar 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 Sept 2025 — TEAS STATEMENT OF USE RECEIVED
- 27 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Apr 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 09 Jan 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 10 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Dec 2024 — PUBLISHED FOR OPPOSITION
- 04 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER